After Johnson & Johnson (JNJ) recently reported that the Phase 2b DUPLEX-AD proof-of-concept study of JNJ-95475939 for the treatment of moderate to severe atopic dermatitis did not meet the bar set for efficacy, BTIG said the firm views this update as “a positive clearing event” for Apogee Therapeutics’ (APGE) APG279 and potentially APG777 as well. The firm reiterates a Buy rating and $115 price target on Apogee shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics price target lowered to $81 from $82 at BofA
- Apogee Therapeutics initiated with an Overweight at Stephens
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/10/2025, According to Top Analysts
- Apogee Therapeutics initiated with a Buy at Deutsche Bank
- Buy Rating for Apogee Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook